FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981636558> ?p ?o ?g. }

• W2981636558 endingPage "287" @default.
• W2981636558 startingPage "274" @default.
• W2981636558 abstract "IntroductionWe assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC.MethodsIn this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. The primary end point was progression-free survival (PFS). Associations of c-Myc expression in tumor tissue (prespecified) and genetic alterations in circulating tumor DNA (retrospective) with clinical outcome were evaluated.ResultsA total of 178 patients were enrolled (89 in each arm). The median PFS was 3.32 months with alisertib/paclitaxel versus 2.17 months with placebo/paclitaxel (hazard ratio [HR] = 0.77, 95% confidence limit [CI]: 0.557–1.067, p = 0.113 in the intent-to-treat population versus HR = 0.71, 95% CI: 0.509–0.985, p = 0.038 with corrected analysis applied). Among 140 patients with genetic alternations, patients with cell cycle regulator mutations (cyclin-dependent kinase 6 gene [CDK6], retinoblastoma-like 1 gene [RBL1], retinoblastoma-like 2 gene [RBL2], and retinoblastoma 1 gene [RB1]) had significantly improved PFS with alisertib/paclitaxel versus with placebo/paclitaxel (3.68 versus 1.80 months, respectively [HR = 0.395, 95% CI: 0.239–0.654, p = 0.0003]), and overall survival (7.20 versus 4.47 months, respectively [HR = 0.427, 95% CI: 0.259–0.704, p = 0.00085]). A subset of patients with c-Myc expression showed significantly improved PFS with alisertib/paclitaxel. The incidence of grade 3 or higher drug-related adverse events was 67% (58 patients) with alisertib/paclitaxel versus 22% (25 patients) with placebo/paclitaxel. Twelve patients (14%) versus 11 (12%) died on study, including four versus zero treatment-related deaths.ConclusionsEfficacy signals were seen with alisertib/paclitaxel in relapsed or refractory SCLC. c-Myc expression and mutations in cell cycle regulators may be potential predictive biomarkers of alisertib efficacy; further prospective validations are warranted." @default.
• W2981636558 created "2019-11-01" @default.
• W2981636558 creator A5000488526 @default.
• W2981636558 creator A5005718112 @default.
• W2981636558 creator A5006417740 @default.
• W2981636558 creator A5006765090 @default.
• W2981636558 creator A5007803338 @default.
• W2981636558 creator A5009590736 @default.
• W2981636558 creator A5010394649 @default.
• W2981636558 creator A5011974968 @default.
• W2981636558 creator A5015060656 @default.
• W2981636558 creator A5015680000 @default.
• W2981636558 creator A5016370905 @default.
• W2981636558 creator A5018054038 @default.
• W2981636558 creator A5019571947 @default.
• W2981636558 creator A5028523965 @default.
• W2981636558 creator A5028746264 @default.
• W2981636558 creator A5030689616 @default.
• W2981636558 creator A5032284029 @default.
• W2981636558 creator A5033599838 @default.
• W2981636558 creator A5039079234 @default.
• W2981636558 creator A5044582889 @default.
• W2981636558 creator A5045317135 @default.
• W2981636558 creator A5050809814 @default.
• W2981636558 creator A5052183772 @default.
• W2981636558 creator A5052476802 @default.
• W2981636558 creator A5053953098 @default.
• W2981636558 creator A5058265665 @default.
• W2981636558 creator A5058967910 @default.
• W2981636558 creator A5059355812 @default.
• W2981636558 creator A5063495695 @default.
• W2981636558 creator A5065691680 @default.
• W2981636558 creator A5067755477 @default.
• W2981636558 creator A5068491805 @default.
• W2981636558 creator A5069979641 @default.
• W2981636558 creator A5078216868 @default.
• W2981636558 creator A5080538468 @default.
• W2981636558 creator A5087219811 @default.
• W2981636558 creator A5088731797 @default.
• W2981636558 date "2020-02-01" @default.
• W2981636558 modified "2023-10-18" @default.
• W2981636558 title "Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses" @default.
• W2981636558 cites W1903523058 @default.
• W2981636558 cites W1932169383 @default.
• W2981636558 cites W1965606913 @default.
• W2981636558 cites W1971264126 @default.
• W2981636558 cites W1981073960 @default.
• W2981636558 cites W1985338536 @default.
• W2981636558 cites W1995474832 @default.
• W2981636558 cites W1996506613 @default.
• W2981636558 cites W2016707341 @default.
• W2981636558 cites W2020917220 @default.
• W2981636558 cites W2038619046 @default.
• W2981636558 cites W2064451512 @default.
• W2981636558 cites W2067056331 @default.
• W2981636558 cites W2073031201 @default.
• W2981636558 cites W2078563859 @default.
• W2981636558 cites W2083904374 @default.
• W2981636558 cites W2090922694 @default.
• W2981636558 cites W2108927999 @default.
• W2981636558 cites W2115891953 @default.
• W2981636558 cites W2141956703 @default.
• W2981636558 cites W2149807418 @default.
• W2981636558 cites W2158127925 @default.
• W2981636558 cites W2159616963 @default.
• W2981636558 cites W2179237675 @default.
• W2981636558 cites W2217920248 @default.
• W2981636558 cites W2229481660 @default.
• W2981636558 cites W2346753737 @default.
• W2981636558 cites W2399797906 @default.
• W2981636558 cites W2421496331 @default.
• W2981636558 cites W2576845640 @default.
• W2981636558 cites W2745840031 @default.
• W2981636558 cites W2892095332 @default.
• W2981636558 cites W2893960509 @default.
• W2981636558 cites W2897708973 @default.
• W2981636558 cites W2899203698 @default.
• W2981636558 cites W4240150408 @default.
• W2981636558 doi "https://doi.org/10.1016/j.jtho.2019.10.013" @default.
• W2981636558 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31655296" @default.
• W2981636558 hasPublicationYear "2020" @default.
• W2981636558 type Work @default.
• W2981636558 sameAs 2981636558 @default.
• W2981636558 citedByCount "84" @default.
• W2981636558 countsByYear W29816365582020 @default.
• W2981636558 countsByYear W29816365582021 @default.
• W2981636558 countsByYear W29816365582022 @default.
• W2981636558 countsByYear W29816365582023 @default.
• W2981636558 crossrefType "journal-article" @default.
• W2981636558 hasAuthorship W2981636558A5000488526 @default.
• W2981636558 hasAuthorship W2981636558A5005718112 @default.
• W2981636558 hasAuthorship W2981636558A5006417740 @default.
• W2981636558 hasAuthorship W2981636558A5006765090 @default.
• W2981636558 hasAuthorship W2981636558A5007803338 @default.
• W2981636558 hasAuthorship W2981636558A5009590736 @default.
• W2981636558 hasAuthorship W2981636558A5010394649 @default.
• W2981636558 hasAuthorship W2981636558A5011974968 @default.
• W2981636558 hasAuthorship W2981636558A5015060656 @default.

• next